RNXT insider transaction filings
RenovoRx, Inc. — 43 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-24. Screen RNXT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | RYAN UNA S — Director | Other (J): 47,789 @ $4.19 · Other (J): 6,332 @ $3.95 · Other (J): 26,838 @ $0.93 · Other (J): 16,206 @ $1.62 | EDGAR |
| 2026-05-21 | 4 | VOLL MARK — Chief Financial Officer | Purchase (P): 25,000 @ $0.79 | EDGAR |
| 2026-04-07 | 4 | Bagai Shaun — Chief Executive Officer, Director | Grant/award (A): 946,107 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Gentry Leesa — Chief Clinical Officer | Grant/award (A): 128,550 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Agah Ramtin — Chief Medical Officer, Director | Grant/award (A): 621,727 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | VOLL MARK — Chief Financial Officer | Grant/award (A): 80,000 @ $0 | EDGAR |
| 2026-03-27 | 4 | VOLL MARK — Chief Financial Officer | Grant/award (A): 12,380 @ $0 | EDGAR |
| 2026-03-24 | 4 | Marton Laurence — Director | Purchase (P): 9,720 · Purchase (P): 4,860 (derivative) | EDGAR |
| 2026-03-24 | 4 | Bagai Shaun — Chief Executive Officer, Director | Purchase (P): 24,300 · Purchase (P): 12,150 (derivative) | EDGAR |
| 2026-03-24 | 4 | VOLL MARK — Chief Financial Officer | Purchase (P): 97,200 · Purchase (P): 48,600 (derivative) | EDGAR |
| 2026-01-22 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 10,000 @ $1.00 | EDGAR |
| 2026-01-05 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 9,795 @ $0.86 | EDGAR |
| 2026-01-02 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 205 @ $0.83 | EDGAR |
| 2025-12-22 | 4 | Bagai Shaun — Chief Executive Officer, Director | Purchase (P): 5,000 @ $0.90 | EDGAR |
| 2025-12-19 | 4 | Bagai Shaun — Chief Executive Officer, Director | Purchase (P): 5,000 @ $0.85 | EDGAR |
| 2025-12-17 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 12,000 @ $0.85 | EDGAR |
| 2025-12-08 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 10,000 @ $0.96 | EDGAR |
| 2025-11-24 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 10,000 @ $0.80 · Purchase (P): 12,000 @ $0.80 | EDGAR |
| 2025-10-03 | 4 | Marton Laurence — Director | Grant/award (A): 47,640 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Macfarlane K. Angela — Director | Grant/award (A): 47,640 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Spiegel Robert J. — Director | Grant/award (A): 47,640 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | RYAN UNA S — Director | Grant/award (A): 47,640 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | Bagai Shaun — Chief Executive Officer, Director | Purchase (P): 5,000 @ $0.95 · Purchase (P): 5,000 @ $0.91 | EDGAR |
| 2025-07-03 | 4 | Agah Ramtin — Chief Medical Officer, Director | Grant/award (A): 63,636 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Bagai Shaun — Chief Executive Officer, Director | Grant/award (A): 102,498 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Gentry Leesa — Chief Clinical Officer | Grant/award (A): 6,619 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Kocak Ron — VP, Controller and PAO | Grant/award (A): 41,600 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 21,000 @ $1.40 | EDGAR |
| 2025-06-06 | 4 | Agah Ramtin — Chief Medical Officer, Director | Gift (G): 400,000 @ $0 | EDGAR |
| 2025-05-06 | 4 | Marton Laurence — Director | Option exercise (M): 20,480 @ $0.15 · Option exercise (M): 20,480 (derivative) @ $0 | EDGAR |
| 2025-04-17 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 15,000 @ $0.90 | EDGAR |
| 2025-04-16 | 4 | Kocak Ron — VP, Controller and PAO | Grant/award (A): 166,400 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Gentry Leesa — Chief Clinical Officer | Grant/award (A): 26,477 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Bagai Shaun — Chief Executive Officer, Director | Grant/award (A): 409,992 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Agah Ramtin — Chief Medical Officer, Director | Grant/award (A): 254,542 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Bagai Shaun — Chief Executive Officer, Director | Purchase (P): 7,500 @ $0.91 | EDGAR |
| 2025-04-14 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 20,000 @ $0.80 | EDGAR |
| 2025-04-10 | 4 | Kocak Ron — VP Controller and PAO | Purchase (P): 95 @ $0.80 · Purchase (P): 6,000 @ $0.80 · Purchase (P): 6,500 @ $0.79 | EDGAR |
| 2025-04-10 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 30,000 @ $0.81 | EDGAR |
| 2025-04-10 | 4 | Bagai Shaun — Chief Executive Officer, Director | Purchase (P): 10,000 @ $0.83 | EDGAR |
| 2025-04-09 | 4 | Marton Laurence — Director | Purchase (P): 12,050 @ $0.85 | EDGAR |
| 2025-04-09 | 4 | Agah Ramtin — Chief Medical Officer, Director | Purchase (P): 26,000 @ $0.84 | EDGAR |
| 2025-04-08 | 4 | Bagai Shaun — Chief Executive Officer, Director | Purchase (P): 10,000 @ $0.83 | EDGAR |
Recent 8-K events — RenovoRx, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-13 | 8-K/A | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-30 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RNXT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →